Europe Cell And Gene Therapy Manufacturing Market Size & Outlook
Global Market
Related Markets
Europe cell and gene therapy manufacturing market highlights
- The Europe cell and gene therapy manufacturing market generated a revenue of USD 1,976.0 million in 2022.
- The market is expected to grow at a CAGR of 26.5% from 2023 to 2030.
- In terms of segment, cell therapy was the largest revenue generating therapy type in 2022.
- Gene Therapy is the most lucrative therapy type segment registering the fastest growth during the forecast period.
- Country-wise, France is expected to register the highest CAGR from 2023 to 2030.
Europe data book summary
| Market revenue in 2022 | USD 1,976.0 million |
| Market revenue in 2030 | USD 12,950.8 million |
| Growth rate | 26.5% (CAGR from 2023 to 2030) |
| Largest segment | Cell therapy |
| Fastest growing segment | Gene Therapy |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, Cell Therapy |
| Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
Other key industry trends
- In terms of revenue, Europe region accounted for 27.1% of the global cell and gene therapy manufacturing market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 23,532.7 million by 2030.
Growing investments on gene & cell therapy companies across European countries is a major driving factor for cell and gene therapy manufacturing market in the European region. Process development and manufacturing for gene & cell therapies are growing at a constant pace in Europe.
Moreover, the European region is at the forefront in terms of providing funds for development and commercialization of cell & gene therapy products as well as R&D activities. For instance, in January 2019, an international research team received funding of approximately USD 7.7 million from the European Union under the Horizon 2020 research & innovation program for the development of nonviral gene delivery technology.
In addition, apceth Biopharma GmbH and Hitachi Chemical Advanced Therapeutic solutions signed an agreement with Bluebird Bio in May 2020 for the expansion of production capacity for Lenti-D for CALD. Such initiatives are anticipated to accelerate market growth in the region.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Cell And Gene Therapy Manufacturing Market Scope
Cell And Gene Therapy Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Hitachi Ltd | View profile | 322,525 | 6-6, Marunouchi 1-chome, Chiyoda-ku, Tokyo, Japan, 100-8280 | www.hitachi.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Takara Bio Inc | View profile | 1,793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | www.takara-bio.co.jp |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
Europe Cell And Gene Therapy Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Cell Therapy was the largest segment with a revenue share of 60.28% in 2022.
Horizon Databook has segmented the Europe cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Growing investments on gene & cell therapy companies across European countries is a major driving factor for cell and gene therapy manufacturing market in the European region. Process development and manufacturing for gene & cell therapies are growing at a constant pace in Europe.
Moreover, the European region is at the forefront in terms of providing funds for development and commercialization of cell & gene therapy products as well as R&D activities. For instance, in January 2019, an international research team received funding of approximately USD 7.7 million from the European Union under the Horizon 2020 research & innovation program for the development of nonviral gene delivery technology.
In addition, apceth Biopharma GmbH and Hitachi Chemical Advanced Therapeutic solutions signed an agreement with Bluebird Bio in May 2020 for the expansion of production capacity for Lenti-D for CALD. Such initiatives are anticipated to accelerate market growth in the region.
- Europe Cell And Gene Therapy Manufacturing Market Therapy Type Outlook (Revenue, USD Million , 2018-2030)
- Gene Therapy
- Cell Therapy
- Europe Cell And Gene Therapy Manufacturing Market Scale Outlook (Revenue, USD Million , 2018-2030)
- Pre-commercial/ R&D Scale
- Commercial Scale
- Europe Cell And Gene Therapy Manufacturing Market Mode Outlook (Revenue, USD Million , 2018-2030)
- Contract manufacturing
- In house manufacturing
- Europe Cell And Gene Therapy Manufacturing Market Workflow Outlook (Revenue, USD Million , 2018-2030)
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical & Quality Testing
- Raw Material Testing
- Vector Production
- Others
- Europe Cell And Gene Therapy Manufacturing Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Malignancies
- Musculoskeletal therapies
- Autoimmune disorders
- Dermatology
- Large B-Cell Lymphoma
- Spinal Muscular Atrophy (SMA)
- Others
Reasons to subscribe to Cell And Gene Therapy Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell And Gene Therapy Manufacturing Market Outlook databook
- Our clientele includes a mix of Cell And Gene Therapy Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Cell And Gene Therapy Manufacturing Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Cell And Gene Therapy Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Europe Cell And Gene Therapy Manufacturing Market, 2018-2030 (US$M)
Europe cell and gene therapy manufacturing market statistics, by therapy type, 2018-2030 (US$M)
